BillionToOne Inc. news

BillionToOne , Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of their UNITY fetal antigen single-gene non-invasive prenatal test (sgNIPT), a new addition to 

BillionToOne, Inc., a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of its first oncology liquid biopsy products, Northstar Select™ and Northstar Response™. The products are currently available for research use with select academic cancer centers.

Northstar Select is a comprehensive pan-cancer somatic mutation profiling panel. Leveraging BillionToOne’s proprietary mo

We deeply thank you for the service you do for the society and for the essential care you provide to pregnant mothers across the US amid this unprecedented pandemic. Our hearts and thoughts go to all of you–you and your family, your clinic staff members, your patients–who have been affected by COVID-19. As a fellow healthcare provider, our team shares the concerns that many of you are feeling every day at work.

At BillionToOne, the medical laboratory

BillionToOne, a venture-backed precision diagnostics company, is presenting series of posters at 2020 ACMG Annual Clinical Genetics Meeting on its single-gene NIPT technology and clinical data.

UNITY improves clinical specificity for cystic fibrosis carrier screening

UNITY is the only prenatal screen that tests cell-free fetal DNA for cystic fibrosis, spinal muscular atrophy (SMA